1.05
price down icon1.87%   -0.02
after-market Handel nachbörslich: 1.06 0.01 +0.95%
loading
Schlusskurs vom Vortag:
$1.07
Offen:
$1.06
24-Stunden-Volumen:
198.59K
Relative Volume:
1.58
Marktkapitalisierung:
$21.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.29M
KGV:
-0.7192
EPS:
-1.46
Netto-Cashflow:
$-17.12M
1W Leistung:
-12.50%
1M Leistung:
-30.92%
6M Leistung:
-25.53%
1J Leistung:
-39.66%
1-Tages-Spanne:
Value
$0.995
$1.085
1-Wochen-Bereich:
Value
$0.995
$1.2312
52-Wochen-Spanne:
Value
$0.995
$4.59

Enlivex Therapeutics Ltd Stock (ENLV) Company Profile

Name
Firmenname
Enlivex Therapeutics Ltd
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
49
Name
Twitter
@EnlivexT
Name
Nächster Verdiensttermin
2024-09-09
Name
Neueste SEC-Einreichungen
Name
ENLV's Discussions on Twitter

Vergleichen Sie ENLV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
ENLV 1.05 21.51M 0 -22.29M -17.12M -1.46
VRTX 467.01 119.87B 10.63B -479.80M -1.35B 13.33
REGN 762.00 83.27B 13.85B 4.65B 3.32B 35.06
ARGX 567.90 33.96B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.18B 2.09B -332.26M 16.06M -4.14
BNTX 101.87 24.42B 3.30B -501.07M 1.03B 11.54

Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-03-02 Bestätigt H.C. Wainwright Buy

Enlivex Therapeutics Ltd Aktie (ENLV) Neueste Nachrichten

pulisher
Nov 16, 2024

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Growth in Short Interest - Defense World

Nov 16, 2024
pulisher
Nov 14, 2024

Armistice Capital, LLC Expands Stake in Enlivex Therapeutics Ltd - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Enlivex Announces the Dosing of the First Patient in a - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Enlivex Launches Phase I Trial for Novel Psoriatic Arthritis Treatment Allocetra™ | ENLV Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Enlivex stock hits 52-week low at $1.15 amid market challenges - Investing.com Canada

Nov 13, 2024
pulisher
Nov 12, 2024

Enlivex Announces the Enrollment and Dosing of the First 10 - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Enlivex's Allocetra Advances: Phase II Trial Launches for Knee Osteoarthritis Treatment | ENLV Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 02, 2024

Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know - MSN

Nov 02, 2024
pulisher
Oct 31, 2024

Enlivex Therapeutics Reschedules Annual Shareholders Meeting - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Enlivex Receives Notice of Allowance for Japanese Patent - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis - StockTitan

Oct 30, 2024
pulisher
Oct 23, 2024

New Strong Buy Stocks for October 23rd - MSN

Oct 23, 2024
pulisher
Oct 23, 2024

New Strong Buy Stocks For October 23rd - Barchart

Oct 23, 2024
pulisher
Sep 29, 2024

Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA By Investing.com - Investing.com South Africa

Sep 29, 2024
pulisher
Sep 28, 2024

Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA - Investing.com Australia

Sep 28, 2024
pulisher
Sep 27, 2024

EF Hutton maintains price target on Enlivex after trial advancement By Investing.com - Investing.com Australia

Sep 27, 2024
pulisher
Sep 26, 2024

Enlivex Advances Knee Osteoarthritis Treatment Trial - TipRanks

Sep 26, 2024
pulisher
Sep 26, 2024

Enlivex Receives Authorization from the Danish Medicines - GlobeNewswire

Sep 26, 2024
pulisher
Sep 26, 2024

Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis - StockTitan

Sep 26, 2024
pulisher
Sep 24, 2024

ENLVEnlivex Therapeutics Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

Enlivex Progresses to Phase II for Knee Arthritis Treatment - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Enlivex Announces Positive DSMB Recommendation to Initiate - GlobeNewswire

Sep 24, 2024
pulisher
Sep 24, 2024

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis - StockTitan

Sep 24, 2024
pulisher
Sep 19, 2024

India News | ⚡Kolkata-Based Company Ellenbarrie Industrial Gases Files IPO Papers - LatestLY

Sep 19, 2024
pulisher
Sep 18, 2024

Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com Canada

Sep 18, 2024
pulisher
Sep 18, 2024

Enliven Therapeutics Announces Details Regarding the - GlobeNewswire

Sep 18, 2024
pulisher
Sep 18, 2024

Ellenbarrie Industrial Gases Files For IPO To Raise Rs 400 Crore - NDTV Profit

Sep 18, 2024
pulisher
Sep 17, 2024

Enmy & The Cure - RAMzine

Sep 17, 2024
pulisher
Sep 13, 2024

ENLV’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Sep 13, 2024
pulisher
Sep 13, 2024

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation - Simply Wall St

Sep 13, 2024
pulisher
Sep 13, 2024

All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy - MSN

Sep 13, 2024
pulisher
Sep 11, 2024

Enlivex Announces 2024 Shareholder Meeting - TipRanks

Sep 11, 2024
pulisher
Sep 10, 2024

Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at HC Wainwright - Defense World

Sep 10, 2024
pulisher
Sep 09, 2024

Enlivex stock poised for growth with key trial readouts by 2025, says H.C. Wainwright - Investing.com India

Sep 09, 2024
pulisher
Aug 30, 2024

Enlivex Therapeutics Financials Indicate Net Loss - TipRanks

Aug 30, 2024
pulisher
Aug 30, 2024

Enlivex Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com

Aug 30, 2024
pulisher
Aug 30, 2024

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire

Aug 30, 2024
pulisher
Aug 30, 2024

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - StockTitan

Aug 30, 2024
pulisher
Aug 28, 2024

Enlivex shares rise on EF Hutton's Buy rating By Investing.com - Investing.com Australia

Aug 28, 2024
pulisher
Aug 27, 2024

Enlivex shares rise on EF Hutton's Buy rating - Investing.com India

Aug 27, 2024
pulisher
Aug 17, 2024

Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 1.9% - Defense World

Aug 17, 2024
pulisher
Jul 23, 2024

Enlivex Advances Psoriatic Arthritis Treatment with Allocetra™ - TipRanks

Jul 23, 2024
pulisher
Jul 23, 2024

Enlivex Receives Regulatory Authorization For The - GlobeNewswire

Jul 23, 2024
pulisher
Jul 23, 2024

Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis - StockTitan

Jul 23, 2024
pulisher
Jul 19, 2024

Enlivex Therapeutics and Biotricity Interviews to Air on the Red - WICZ

Jul 19, 2024
pulisher
Jul 19, 2024

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire

Jul 19, 2024
pulisher
Jul 17, 2024

CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent - openPR

Jul 17, 2024
pulisher
Jul 17, 2024

CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV) - Barchart

Jul 17, 2024
pulisher
Jul 05, 2024

Enlivex Therapeutics (NASDAQ:ENLV) Trading 0.6% Higher - Defense World

Jul 05, 2024
pulisher
Jun 24, 2024

Enlivex Commences Key Trial for Thumb Osteoarthritis - TipRanks

Jun 24, 2024
pulisher
Jun 24, 2024

Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating ... - Yahoo Finance

Jun 24, 2024

Finanzdaten der Enlivex Therapeutics Ltd-Aktie (ENLV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
Kapitalisierung:     |  Volumen (24h):